eIF4B Activators
The chemical class of eIF4B activators comprises a range of compounds that can directly or indirectly modulate the activation of eIF4B, a crucial player in translation initiation. 4EGI-1 disrupts the eIF4E/eIF4G interaction, indirectly influencing eIF4B activation by impacting the eIF4F complex. Rapamycin and LY2584702 target the mTOR pathway, indirectly regulating eIF4B through mTOR-mediated translation initiation. Rocaglamide inhibits eIF4A helicase activity, indirectly affecting eIF4B by disrupting mRNA secondary structure unwinding. CGP 57380 inhibits p38 MAP kinase, influencing eIF4B activation through its regulatory pathways. PF-4708671 inhibits AMPK, indirectly impacting eIF4B by modulating the negative regulation from the AMPK-mTOR axis. CCG-1423 affects Rho/MRTF/SRF signaling, indirectly modulating eIF4B activation connected to various cellular cascades.
BI-D1870 inhibits RSK, indirectly influencing eIF4B activation through the MAPK pathway. ISRIB enhances eIF2B activity, indirectly impacting eIF4B through eIF2B-mediated translation initiation. TAK-632 inhibits MEK, indirectly modulating eIF4B through the MAPK/ERK pathway. SBI-0640756 inhibits PERK, indirectly influencing eIF4B through the unfolded protein response (UPR) pathway. CCT020312 inhibits MNK1/2, indirectly modulating eIF4B by altering eIF4E phosphorylation status. This diverse array of eIF4B activators provides researchers with valuable tools to explore the intricate regulation of translation initiation processes in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | 315706-13-9 | sc-202597 | 10 mg | $265.00 | 14 | |
4EGI-1 is a small molecule inhibitor of the eIF4E/eIF4G interaction. By disrupting the eIF4E and eIF4G association, it indirectly affects the eIF4F complex, potentially modulating eIF4B activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, can indirectly influence eIF4B activation. As mTOR regulates the translation initiation process, including the activity of eIF4B, rapamycin's inhibition of mTOR can impact eIF4B function. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide is a natural compound that inhibits the eIF4A helicase activity. As eIF4A is involved in unwinding mRNA secondary structures during translation initiation, rocaglamide's inhibition of eIF4A can impact eIF4B activation indirectly. | ||||||
CGP 57380 | 522629-08-9 | sc-202993 | 5 mg | $172.00 | 6 | |
CGP 57380 is a chemical inhibitor of p38 MAP kinase. As p38 MAP kinase is implicated in the regulation of eIF4B, CGP 57380's inhibition of p38 MAP kinase can indirectly influence eIF4B activation by modulating its regulatory pathways. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671 is an AMP-activated protein kinase (AMPK) inhibitor. As AMPK can negatively regulate mTOR and subsequently eIF4B, PF-4708671's inhibition of AMPK can indirectly impact eIF4B activation by influencing the mTOR signaling pathway. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 is an inhibitor of Rho/MRTF/SRF transcriptional signaling. By affecting this signaling pathway, CCG-1423 can indirectly modulate eIF4B activation, as eIF4B regulation is intricately connected with various cellular signaling cascades. | ||||||
BI-D1870 | 501437-28-1 | sc-397022 sc-397022A | 1 mg 5 mg | $92.00 $260.00 | 12 | |
BI-D1870 is a chemical inhibitor of RSK (p90 ribosomal S6 kinase), which plays a role in regulating eIF4B through the MAPK pathway. Its inhibition of RSK can indirectly influence eIF4B activation by modulating the downstream signaling pathways. | ||||||
ISRIB | 1597403-47-8 | sc-488404 | 10 mg | $300.00 | 1 | |
ISRIB is a small molecule that enhances eIF2B activity. As eIF2B is involved in the regulation of translation initiation, including eIF4B activation, ISRIB's action on eIF2B can indirectly modulate eIF4B function. | ||||||
TAK 632 | 1228591-30-7 | sc-473801 | 5 mg | $228.00 | ||
TAK-632 is a potent and selective MEK inhibitor. By affecting the MAPK/ERK pathway through MEK inhibition, TAK-632 can indirectly modulate eIF4B activation, as the MAPK/ERK pathway is intricately connected with translation initiation regulation. | ||||||